Bone and joint diseases in children. Bisphosphonates in osteogenesis imperfecta
Yamashita, S.
Clinical Calcium 20(6): 918-924
2010
ISSN/ISBN: 0917-5857 PMID: 20513950 Document Number: 645403
Osteogenesis imperfecta (OI) is a genetic disorder characterized by fragile bone and reduced bone mineral density. Cyclic intravenous pamidronate is now the most widely used treatment for moderate to severe forms of OI. Oral bisphosphonates provide clinical benefit and convenience to the patients with mild form of OI. Recently, some studies demonstrated that intravenous zolendronate in children with OI is safe in short-term and similarly effective to parmidronate. Optimal dose, duration of treatment and long-term safety of newer bisphosphonates require further investigations.
Document emailed within 1 workday
